Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/0333102416648328 http://scihub22266oqcxt.onion/10.1177/0333102416648328 C5394468!5394468!27154997     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cephalalgia 2017 ; 37 (4): 356-64 Nephropedia Template TP {{tp|p=27154997|t=2017. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine |pdf=|usr=}}{{27154997}} gab.com Text Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine JO: Cephalalgia http://www.kidney.de/pget.php?&tw=1&pmid=27154997 #FOAvip Objective: The main objective of this pilot study was to investigate the safety of administering onabotulinumtoxinA towards the sphenopalatine ganglion in 10 patients with intractable chronic migraine with an open, uncontrolled design. We also collected efficacy data to provide an indication as to whether future placebo-controlled studies should be performed. Method: In a prospective, open-label, uncontrolled study after one-month baseline, we performed bilateral injections of 25?IU onabotulinumtoxinA (total dose 50?IU) toward the sphenopalatine ganglion in a single outpatient session in 10 patients with intractable migraine with a follow-up of 12 weeks. The primary outcome was adverse events and the main efficacy outcome was frequency of moderate and severe headache days in month 2 post-treatment compared to baseline. Results: All 10 patients experienced a total of 25 adverse events. The majority of these were different types of local discomfort in the face and jaw, and none were classified as serious. In an intention-to-treat analysis of the main efficacy outcome, a statistically significant reduction of moderate and severe headache days in baseline versus month 2 was observed (16.3?±?6.2 days baseline versus 7.6?±?7.6 days month 2, p?=?0.009). Eight out of 10 patients experienced an at least 50% reduction of moderate and severe headache days compared to baseline. Conclusion: The result warrants randomised, placebo-controlled studies to establish both safety and efficacy of this potential novel treatment of chronic migraine. Twit Text FOAVip Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine ????Cephalalgia http://www.kidney.de/pget.php?&tw=1&pmid=27154997 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27154997 #FOAvip English Wikipedia <ref>{{Cite pmid|27154997}}</ref> Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine #MMPMID27154997 Bratbak DF; Nordgård S; Stovner LJ; Linde M; Dodick DW; Aschehoug I; Folvik M; Tronvik E Cephalalgia 2017[Apr]; 37 (4): 356-64 PMID27154997show ga Objective: The main objective of this pilot study was to investigate the safety of administering onabotulinumtoxinA towards the sphenopalatine ganglion in 10 patients with intractable chronic migraine with an open, uncontrolled design. We also collected efficacy data to provide an indication as to whether future placebo-controlled studies should be performed. Method: In a prospective, open-label, uncontrolled study after one-month baseline, we performed bilateral injections of 25?IU onabotulinumtoxinA (total dose 50?IU) toward the sphenopalatine ganglion in a single outpatient session in 10 patients with intractable migraine with a follow-up of 12 weeks. The primary outcome was adverse events and the main efficacy outcome was frequency of moderate and severe headache days in month 2 post-treatment compared to baseline. Results: All 10 patients experienced a total of 25 adverse events. The majority of these were different types of local discomfort in the face and jaw, and none were classified as serious. In an intention-to-treat analysis of the main efficacy outcome, a statistically significant reduction of moderate and severe headache days in baseline versus month 2 was observed (16.3?±?6.2 days baseline versus 7.6?±?7.6 days month 2, p?=?0.009). Eight out of 10 patients experienced an at least 50% reduction of moderate and severe headache days compared to baseline. Conclusion: The result warrants randomised, placebo-controlled studies to establish both safety and efficacy of this potential novel treatment of chronic migraine. äPilot study of sphenopalatine injection of onabotulinumtoxinA for the (epmc).pdf DeepDyve Pubget Overpricing